Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer

Lung Cancer

Volumn 39, Issue 2, 2003, Pages 197-199

  Edelman, Martin J ^a,e   Gandara, David R ^b   Hausner, Petr ^a,e   Israel, Valerie ^c   Thornton, Donald ^d   DeSanto, Jennifer ^a   Doyle, L Austin ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Cryptophycin 52; Non small cell lung cancer; Second line therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CRYPTOPHYCIN 52;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALAISE; MALE; NAUSEA; NEUROPATHY; PAIN; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PLEURA EFFUSION; PRIORITY JOURNAL; TOXICITY TESTING; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DEPSIPEPTIDES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTAMS; LACTONES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0037316411     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00511-1     Document Type: Article

References (14)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA: Cancer J. Clin. 52:2002;23-47.
2. Edelman M.J., Gandara D.R. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother. Pharmacol. 37:1996;385-393.
3. Gandara DR, Edelman MJ, Lara P, et al.Current status and novel therapeutic approaches in advanced non-small cell lung cancer. ASCO Educational Book. Spring 1999:362-369.
4. Kelly K., Crowley J., Bunn P.A., et al. Randomized phase three trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19:2001;3210-3218.
5. Sandler A., Nemunatis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced and metastatic non-small cell lung cancer. J. Clin. Oncol. 18:2000;122-130.
6. Fossella F.V., DeVore R., Kerr R., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J. Clin. Oncol. 18:2000;2354-2362.
7. Shepherd F., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel vs. best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2113.
8. Schwartz R.E., Hirsch C.F., Sesin D.F., Flor J.E., Chartrain M., Fromtling R.E., et al. Pharmaceuticals from cultured algae. J. Ind. Microbiol. 5:1990;113-124.
9. Trimurtulu G., Ohtani I., Patterson G.M.L., Moore R.E., Corbett T.H., Valeriote F.A., Demchik L. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga, Nostoc sp., Strain GSV. J. Am. Chem. Soc. 116:1994;4729-4737.
10. Rowinsky E.K., Donehower R.C. Microtubule-targeting drugs. Perry M.C. The Chemotherapy Source Book. 2nd edition:1996;387-423 Williams and Wilkins, Baltimore.
11. Wagner M.M., Paul D.C., Shih C., Jordan M.A., Wilson L., Williams D.C. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother. Phamacol. 43:1999;115-125.
12. Stevenson J.P., Gallagher M., Vaughn D., et al. Phase I trial of the cryptophycin analogue LY355703 administered as an IV infusion, D1 and D8, repeated every 21 days. Proc. Am. Assoc. Cancer Res. Annu. Meet. 40:1999;92.
13. Green S., Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs. 10:1992;239-253.
14. Groth G., Schott K., Ohnmacht U., Manegold C., Gatzemeier U. A phase II study of LY355703 (cryptophycine) as first-line therapy for stage IIIb or IV NSCLC subjects: preliminary analysis. Eur. J. Cancer. 37:(Suppl. 6):2001;48.